Amendment No. (for drafter's use only)

	CHAMBER ACTION
	<u>Senate</u> <u>House</u>
1	
2	
3	
4	
5	
6	
7	
8	
9	
0	
1	Representative Ryan offered the following:
2	
3	Amendment
14	Remove lines 429-469, and insert:
15	
6	(a) The grantee shall reinvest a percentage of the net
7	royalty revenues and of the revenues from the sale of stock
8	received by The Scripps Research Institute from the licensing or
9	transfer of inventions, methods, processes, and other patentable
20	activities conceived or reduced to practice using facilities or
21	employees of the grantee following the execution of the contract
22	between the corporation and the grantee, as provided in
23	paragraph (c). For purposes of this paragraph, the term "net
24	royalty revenues" means all royalty revenues less the cost of
25	obtaining, maintaining, and enforcing related patent and
26	intellectual property rights, both foreign and domestic.

Reinvestment payments under this subsection shall commence no

Amendment No. (for drafter's use only)

- later than 6 months after the grantee has received the final disbursement under the contract and continue until the grantee has reinvested pursuant to paragraph (c) the percentage of all the net royalty revenues and proceeds from the sale of stock related to the grantee's operation after the execution of the contract.
- (b) The grantee shall reinvest a percentage of the gross revenues it receives from naming opportunities associated with any facility it builds in this state, as provided in paragraph (c). For purposes of this paragraph, the term "naming opportunities" includes charitable donations from any person in consideration for the right to have all or a portion of the facility named for or in the memory of any person, living or dead, or for any entity. The obligation to make reinvestment payments under this subsection shall commence upon the execution of the contract between the corporation and the grantee.
- (c) The total amount of revenues reinvested by the grantee under this subsection shall be:
- 1. Fifteen percent of up to \$155 million in such revenues, or \$200 million if performance measures are not met.
- 2. Ten percent thereafter up to \$300 million in such revenues, or \$369 million if performance measures are not met.
 - 3. Five percent thereafter.

All reinvestment payments made pursuant to this subsection shall be remitted to the state for deposit in the Biomedical Research Trust Fund, or if such fund has ceased to exist, in another trust fund that supports biomedical research, as determined by law.